What are hypomethylating agents and when are they used for MDS?
MDS experts, Dr Alan List and Dr David Sallman, provide an overview of hypomethylating agents for the treatment of myelodysplastic syndromes (MDS). These medications work by turning on genes to kill the cancer cells. Examples discussed are azacitidine and decitabine. The doctors describe how these drugs are given, how they work, and potential side effects.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by charitable grants from Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their health care professionals for optimal outcomes.